Wondfo’s Malaria P.f (HRP2/pLDH) Test has passed the pre-qualification of the World Health Organization (WHO)

On July 30, 2024, Wondfo's Malaria P.f (HRP2/pLDH) Test has passed the pre-qualification of the World Health Organization (WHO) and has been included in the Recommended Procurement List of In Vitro Diagnostic products by the WHO.

After the One Step HIV 1/2 Whole Blood/ Serum/ Plasma Test and HIV self-test products passed the WHO PQ certification, the performance of our products and the company's quality management system have once again gained international recognition. Wondfo will work together with global organizations to address global threats and challenges, and will continue working on the prevention and treatment of malaria and the protection of human health worldwide.

According to the World Malaria Report 2023 released by WHO, global malaria cases increased by 5 million to 249 million in 2022, and WHO indicated that early diagnosis and treatment of malaria can reduce cases, prevent deaths, and help reduce transmission, and recommended that all suspected malaria cases should be confirmed by parasite diagnostic tests (microscopy or rapid diagnostic tests).

Wondfo’s Malaria P.f (HRP2/pLDH) Test is based on colloidal gold immunochromatography and is used for the qualitative detection of Plasmodium falciparum-specific histidine-rich protein-2 (P.f HRP2) and Plasmodium falciparum-specific lactate dehydrogenase (P.f PLDH) in both finger and venous whole blood. It can be used as a diagnostic test for symptomatic patients, including pediatric screening, effectively improving the efficiency of and accessibility to malaria testing services.

Since the launch of the first malaria test in 2010, Wondfo has continued to provide technical support for global malaria control, covering more than 100 countries and regions around the world. Wondfo will always be “Racing for Life” and continue to drive high-quality development through scientific research to make biotechnology benefit all.

Choose your location